


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



溫州康寧醫院股份有限公司
Wenzhou Kangning Hospital Co., Ltd.

(A joint stock limited liability company incorporated in the People's Republic of China)
 Stock code: 2120

**PRINCIPAL OPERATING DATA AND INDICATORS
 FOR THE THREE MONTHS ENDED MARCH 31, 2023
 AND THE FIRST QUARTER 2023**

This is a voluntary announcement made by Wenzhou Kangning Hospital Co., Ltd. (the “**Company**”) to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the “**Group**”).

The table below sets forth the relevant operating data and indicators of the Group’s owned hospitals by inpatients and outpatients for the three months ended March 31, 2023 with comparative figures for the three months ended March 31, 2022:

	For the three months ended March 31,		
	2023	2022	Year-on-year changes
Inpatients			
Number of inpatient bed-days	769,749	718,866	7.1%
Average inpatient spending per bed-day on treatment and general healthcare services (<i>RMB</i>)	350	339	3.2%
Average inpatient spending per bed-day on pharmaceutical sales (<i>RMB</i>)	53	50	6.0%
Total average inpatient spending per bed-day (<i>RMB</i>)	<u>403</u>	<u>389</u>	<u>3.6%</u>
Outpatients			
Number of outpatient visits	124,671	112,280	11.0%
Average outpatient spending per visit on treatment and general healthcare services (<i>RMB</i>)	125	112	11.6%
Average outpatient spending per visit on pharmaceutical sales (<i>RMB</i>)	276	316	-12.7%
Total average outpatient spending per visit (<i>RMB</i>)	<u>401</u>	<u>428</u>	<u>-6.3%</u>

Notes:

1. The above total average inpatient spending per bed-day is determined based on the Company's bills for services provided to patients, without taking into account differences with medical insurance settlements and the Company's income deduction for some medical expenses that may not be received.
2. The above data of number of outpatient visits and average outpatient spending per visit on treatment and general healthcare services are excluding the business of the COVID-19 nucleic acid test.

The above operating data and indicators are based on the Company's records and have not been audited or reviewed by the Company's auditor. The operating data and indicators may be different from those disclosed in relevant periodical reports. The operating data and indicators disclosed in relevant periodical reports shall prevail if there is any discrepancy.

CONTINUED SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on April 1, 2022. Trading in the shares of the Company will remain suspended until further notice.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Wenzhou Kangning Hospital Co., Ltd.
GUAN Weili
Chairman

Zhejiang, the PRC
April 4, 2023

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili and Ms. WANG Lianyue; the non-executive directors are Mr. QIN Hao and Mr. LI Changhao; and the independent non-executive directors are Ms. ZHONG Wentang and Mr. LIU Ning.